Literature DB >> 27369118

Surgical results for pulmonary atresia with intact ventricular septum: a single-centre 15-year experience and medium-term follow-up.

Jinghao Zheng1, Botao Gao1, Zhongqun Zhu1, Guocheng Shi1, Zhiwei Xu1, Jinfen Liu1, Xiaomin He2.   

Abstract

OBJECTIVES: The optimal surgical strategies for pulmonary atresia with intact ventricular septum (PAIVS) are still not well established. This study reviewed our 15-year experience in the management of PAIVS.
METHODS: Between July 1999 and June 2014, 170 patients were treated for PAIVS in our heart centre. Based on the morphology of the right ventricle (RV), age and surgical approaches, the patients were divided into two groups: the one-stage surgery group (n = 33) and the staged surgery group (n = 137), in which patients received definitive repair, including biventricular repair, 1.5 ventricular repair and univentricular palliation without or with initial intervention. The median follow-up time was 6.6 years (range: 1-15 years); survival rates, risk factors for death and clinical status after operation were assessed.
RESULTS: In the one-stage surgery group, there were three deaths post operation; the estimated 1-, 5- and 15-year survival rates were 97.0, 93.7 and 88.5%, respectively. In the staged surgery group, 23 patients died, including 15 in the waiting period after initial intervention. The estimated 1-, 5- and 15-year survival rates of the staged group were 89.8, 88.2 and 69.1%, without significant difference when compared with the one-stage surgery group (P > 0.05). Independent predictors of mortality were severe RV hypoplasia (P < 0.05) and lower tricuspid valve Z-scores (P < 0.01). At the latest follow-up, most of the patients in both groups had a good clinical status after definitive repair. The re-operation rate was 16.0% (4/25) in the one-stage surgery group compared with 15.4% (6/39) in the staged surgery group.
CONCLUSIONS: Both one-stage repair and the staged surgical procedure had acceptable surgical outcomes in this retrospective study. Initial intervention is suitable for neonates or younger patients to promote the growth of the RV, and one-stage definitive repair is a beneficial choice for older patients with PAIVS, in whom the growth potential of the RV is limited.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Congenital heart disease; Follow-up; Pulmonary atresia with intact ventricular septum; Surgical treatment; Transcatheter management

Mesh:

Year:  2016        PMID: 27369118     DOI: 10.1093/ejcts/ezw226

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Long-term outcomes after intervention for pulmonary atresia with intact ventricular septum.

Authors:  Lydia K Wright; Jessica H Knight; Amanda S Thomas; Matthew E Oster; James D St Louis; Lazaros K Kochilas
Journal:  Heart       Date:  2019-02-02       Impact factor: 5.994

2.  Predictors of Mortality in Children with Pulmonary Atresia with Intact Ventricular Septum.

Authors:  Stephanie Grant; David Faraoni; James DiNardo; Kirsten Odegard
Journal:  Pediatr Cardiol       Date:  2017-09-04       Impact factor: 1.655

3.  MDCT evaluation of intramyocardial-sinusoids-coronary artery communications in a neonate with pulmonary atresia and intact ventricular septum.

Authors:  Karuna M Das; Taleb M Almansoori; Tarek Suliman Momenah; Klaus Neidl-Van Gorkom
Journal:  Indian J Radiol Imaging       Date:  2020-03-30

4.  Human phenotype ontology annotation and cluster analysis for pulmonary atresia to unravel clinical outcomes.

Authors:  Bingyan Shu; Huayan Shen; Xinyang Shao; Fengming Luo; Tianjiao Li; Zhou Zhou
Journal:  Front Cardiovasc Med       Date:  2022-07-29

5.  Transthoracic Balloon Pulmonary Valvuloplasty for Treatment of Congenial Pulmonary Atresia Patients with Intact Ventricular Septum.

Authors:  Zhi-Qin Lin; Qiang Chen; Hua Cao; Liang-Wan Chen; Gui-Can Zhang; Dao-Zhong Chen; Qin-Min Wang; Han-Fan Qiu; Dong-Shan Liao; Feng Lin
Journal:  Med Sci Monit       Date:  2017-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.